Ocugen Inc. [NASDAQ: OCGN] traded at a low on 11/06/20, posting a -2.41 loss after which it closed the day’ session at $0.28. The company report on November 6, 2020 that Ocugen Provides Business Update and Third Quarter 2020 Financial Results.
First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021.
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to cure blindness diseases, reported third quarter 2020 financial results along with a general business update.
The results of the trading session contributed to over 4564365 shares changing hands. Over the past one week, the price volatility of Ocugen Inc. stands at 8.17% while the volatility over the past one month is 6.41%.
The market cap for OCGN stock reached $47.23 million, with 162.03 million shares outstanding and 129.86 million shares in the current float. Compared to the average trading volume of 10.83M shares, OCGN reached a trading volume of 4564365 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ocugen Inc. [OCGN]?
The Average True Range (ATR) for Ocugen Inc. is set at 0.02, with the Price to Sales ratio for OCGN stock in the period of the last 12 months amounting to 1108.17. The Price to Book ratio for the last quarter was 1.56, with the Price to Cash per share for the same quarter was set at 0.09.
How has OCGN stock performed recently?
Ocugen Inc. [OCGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.21. With this latest performance, OCGN shares dropped by -17.36% in over the last four-week period, additionally sinking by -15.15% over the last 6 months – not to mention a drop of -75.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OCGN stock in for the last two-week period is set at 37.60, with the RSI for the last a single of trading hit 34.86, and the three-weeks RSI is set at 41.03 for Ocugen Inc. [OCGN]. The present Moving Average for the last 50 days of trading for this stock 0.3208, while it was recorded at 0.2827 for the last single week of trading, and 0.3619 for the last 200 days.
Ocugen Inc. [OCGN]: Deeper insight into the fundamentals
Ocugen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.30.
Earnings analysis for Ocugen Inc. [OCGN]
With the latest financial reports released by the company, Ocugen Inc. posted -4.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.6/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -700.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OCGN.
Insider trade positions for Ocugen Inc. [OCGN]
There are presently around $2 million, or 6.20% of OCGN stock, in the hands of institutional investors. The top three institutional holders of OCGN stocks are: BLACKROCK INC. with ownership of 5,018,690, which is approximately 676.905% of the company’s market cap and around 0.10% of the total institutional ownership; CITADEL ADVISORS LLC, holding 465,972 shares of the stock with an approximate value of $0.13 million in OCGN stocks shares; and WINTON GROUP LTD, currently with $0.1 million in OCGN stock with ownership of nearly 103.764% of the company’s market capitalization.
10 institutional holders increased their position in Ocugen Inc. [NASDAQ:OCGN] by around 5,245,566 shares. Additionally, 8 investors decreased positions by around 1,065,549 shares, while 5 investors held positions by with 788,200 shares. The mentioned changes placed institutional holdings at 7,099,315 shares, according to the latest SEC report filing. OCGN stock had 4 new institutional investments in for a total of 172,163 shares, while 5 institutional investors sold positions of 222,530 shares during the same period.